{"id":"W4210463828","doi":"10.1016/s2468-1253(21)00382-4","title":"Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study","year":2022,"lang":"en","type":"article","venue":"˜The œLancet. Gastroenterology & hepatology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; Principia Biopharma; National Institutes of Health; BioMarin Pharmaceutical; Silverback Therapeutics; Puma Biotechnology; F-star Therapeutics; Genentech; AstraZeneca; Alexion Pharmaceuticals; Celldex Therapeutics; Amgen; Pfizer","keywords":"Medicine; Pembrolizumab; Internal medicine; Clinical endpoint; Anal cancer; Cohort; Adverse effect; Surgery; Cancer; Phases of clinical research; Clinical trial; Oncology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002550232,0.001147802,0.002711918,0.0002286612,0.0002872824,0.001034595,0.0006972968,0.001394537,0.004065077],"category_scores_gemma":[0.002668645,0.0004877462,0.002103299,0.0003774594,0.0005197976,0.001137592,0.0004673452,0.002003792,0.0008235282],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006630626,"about_ca_system_score_gemma":0.0006243741,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007730293,"about_ca_topic_score_gemma":0.001779107,"domain_scores_codex":[0.9989771,0.0006397633,0.00005974865,0.0001251345,0.00008509344,0.0001131851],"domain_scores_gemma":[0.9989142,0.0004029729,0.0002701387,0.000129134,0.00008657817,0.0001968952],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9547358,0.002488571,0.002209137,0.002050164,0.005919208,0.0000852548,0.00007993838,0.0004006349,0.00370238,0.0001170952,0.001572005,0.02663985],"study_design_scores_gemma":[0.939186,0.04210802,0.01242626,0.0001418295,0.003661893,0.0001097913,0.00005267039,0.0002153579,0.0003313766,0.0002129169,0.001529031,0.00002475651],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9781089,0.01510533,0.0006073936,0.0007612609,0.0004584869,0.001308564,0.001643044,0.0000555293,0.001951505],"genre_scores_gemma":[0.9862431,0.005239116,0.0009809267,0.001362897,0.0003127982,0.001556941,0.001861246,0.00002617464,0.002416698],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004065077,"threshold_uncertainty_score":0.01359898,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02118178989392829,"score_gpt":0.2783420517374179,"score_spread":0.2571602618434896,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}